News & Updates

Muscle loss persists in leukaemia patients on nutrition therapy

09 Jan 2025

Muscle or fat-free mass (FFM) decreases in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) undergoing intensive chemotherapy despite medical nutrition therapy (MNT), reports a recent study. Fat mass, on the other hand, remains unchanged.

Muscle loss persists in leukaemia patients on nutrition therapy

09 Jan 2025

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

09 Jan 2025 by

A phase III trial (LUNA 3) has demonstrated robust therapeutic effects for rilzabrutinib in patients with previously untreated immune thrombocytopenia (ITP). Use of this BTK inhibitor results in rapid and durable platelet response, reduced bleeding and need for rescue therapy, improved physical fatigue and quality of life (QoL), and favourable safety and tolerability.

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

09 Jan 2025

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Pregnant women with nonalcoholic fatty liver disease (NAFLD) face a greater risk of adverse pregnancy events, suggests a genome-wide association study.

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Oral bacteria a risk factor for HNSCC development

09 Jan 2025 by

A prospective nested case-control study yields compelling evidence that oral bacteria are a risk factor for the development of head and neck squamous cell carcinoma (HNSCC), which comprises cancers of the oral cavity, pharynx, and larynx.

Oral bacteria a risk factor for HNSCC development

09 Jan 2025

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success

09 Jan 2025

In the treatment of invasive infections due to multidrug-resistant P. aeruginosa, the use of ceftolozane–tazobactam combination appears to yield higher rates of clinical success than the ceftazidime–avibactam combination, according to an observational study.

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success

09 Jan 2025

Smartphone-based app highly sensitive for detecting neonatal jaundice

08 Jan 2025 by

A smartphone-based application that integrates machine learning technology holds promise as a screening tool for neonatal jaundice, demonstrating good correlation and agreement with total serum bilirubin (TSB).

Smartphone-based app highly sensitive for detecting neonatal jaundice

08 Jan 2025

Hydroxyurea for HbSC tied to fewer vaso-occlusive events, hospitalizations

08 Jan 2025 by

Treatment with hydroxyurea at 20 mg/kg/day results in significantly fewer painful vaso-occlusive events and fewer hospitalization in patients with haemoglobin (Hb) sickle cell (HbSC) disease, indicating its effective disease-modifying effect. It is also well-tolerated in both children and adults with HbSC.

Hydroxyurea for HbSC tied to fewer vaso-occlusive events, hospitalizations

08 Jan 2025

Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC

08 Jan 2025 by

First-line treatment with osimertinib plus platinum-pemetrexed chemotherapy (CTx) induces significant improvements in progression-free survival (PFS) among Asian patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), which is similar with the results seen in the global population of the FLAURA2 study.

Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC

08 Jan 2025

Adolescent discrimination exposure ups risk of psychological distress

08 Jan 2025

Discrimination exposure during adolescence may affect the neural response to future stressors, particularly within regions associated with emotion expression and regulation. As a result, this may alter the individual’s vulnerability and resilience to psychological distress, suggests a study.

Adolescent discrimination exposure ups risk of psychological distress

08 Jan 2025

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

08 Jan 2025

The small-interfering RNA zerlasiran appears promising in the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), reducing time time-averaged lipoprotein(a) concentration by more than 80 percent over 36 weeks of follow-up, as shown in a phase II trial.

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

08 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Muscle loss persists in leukaemia patients on nutrition therapy

Muscle loss persists in leukaemia patients on nutrition therapy

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

Maternal NAFLD ups risk of adverse pregnancy outcomes

Maternal NAFLD ups risk of adverse pregnancy outcomes

Oral bacteria a risk factor for HNSCC development

Oral bacteria a risk factor for HNSCC development

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success

Ceftolozane–tazobactam for resistant P. aeruginosa infections linked to high clinical success

Smartphone-based app highly sensitive for detecting neonatal jaundice

Smartphone-based app highly sensitive for detecting neonatal jaundice

Hydroxyurea for HbSC tied to fewer vaso-occlusive events, hospitalizations

Hydroxyurea for HbSC tied to fewer vaso-occlusive events, hospitalizations

Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC

Osimertinib plus chemo extends survival in Asians with EGFR-mutated advanced NSCLC

Adolescent discrimination exposure ups risk of psychological distress

Adolescent discrimination exposure ups risk of psychological distress

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial